BioCentury | Mar 16, 2017
Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
BioCentury | Oct 13, 2016
Product R&D

Elastic bones

...strategic alliance with Bone Biologics Corp. , which is developing recombinant NELL1 for bone repair. In June, Bone Biologics...
...between the groups to use the protein to promote bone regeneration during spinal fusion procedures. Bone Biologics...
...effects in mice, suggesting the protein might have a better safety profile than BMP2. Now Bone Biologics...
BioCentury | Jun 27, 2016
Company News

UCLA, Bone Biologics deal

...UCLA granted Bone Biologics an option to license exclusive, worldwide rights to use NEL-like protein 1 (NELL1...
...option to license exclusive, worldwide rights to use NEL-like protein 1 (NELL1) to treat osteoporosis. Bone Biologics...
...bone regeneration in spinal fusion procedures, which is also under an exclusive license from UCLA. Bone Biologics...
BioCentury | Mar 7, 2016
Financial News

Bone Biologics completes private placement of convertible notes

...investor also received a five-year warrant to purchase up to 1.9 million shares at $2.05. Bone Biologics...
BioCentury | Mar 7, 2016
Financial News

Bone Biologics completes private placement

...million Price: $2.05 Shares after offering: 33.3 million Investors: Musculoskeletal Transplant Foundation; Orthofix Inc. Note: Bone Biologics...
BioCentury | May 11, 2015
Financial News

Bone Biologics completes venture financing

Bone Biologics Corp. , Edison, N.J. Business: Musculoskeletal Date completed: 2015-05-04 Type: Venture financing Raised: $2 million Investor: Hankey Capital Note: The convertible note matures on May 4, 2018, bears interest at the prime rate plus...
BioCentury | Nov 24, 2014
Company News

Bone Biologics management update

Bone Biologics Corp. , Edison, N.J. Business: Musculoskeletal Hired: Deina Walsh as CFO WIR Staff Musculoskeletal...
BioCentury | Mar 15, 2010
Financial News

Bone Biologics completes venture financing

Bone Biologics Inc. , Thousand Oaks, Calif. Business: Musculoskeletal Date completed: 3/10/10 Type: Venture financing Raised: Undisclosed Investor: Musculoskeletal Transplant Foundation Note: The investor also provided an undisclosed line of credit. WIR Staff Musculoskeletal Transplant...
BioCentury | Mar 15, 2010
Company News

Bone Biologics board of directors update

Bone Biologics Inc. , Thousand Oaks, Calif. Business: Musculoskeletal Appointed: Mark Spilker, VP of R&D at the Musculoskeletal Transplant Foundation WIR Staff...
BioCentury | Mar 2, 2009
Clinical News

Bone Biologics preclinical data

...Data from a primate model of spinal bone fusion surgery showed that Bone Biologics' UCB-1 combined with...
...matrix is from the Musculoskeletal Transplant Foundation, a non-profit consortium dedicated to providing allograft tissue. Bone Biologics...
Items per page:
1 - 10 of 18
BioCentury | Mar 16, 2017
Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
BioCentury | Oct 13, 2016
Product R&D

Elastic bones

...strategic alliance with Bone Biologics Corp. , which is developing recombinant NELL1 for bone repair. In June, Bone Biologics...
...between the groups to use the protein to promote bone regeneration during spinal fusion procedures. Bone Biologics...
...effects in mice, suggesting the protein might have a better safety profile than BMP2. Now Bone Biologics...
BioCentury | Jun 27, 2016
Company News

UCLA, Bone Biologics deal

...UCLA granted Bone Biologics an option to license exclusive, worldwide rights to use NEL-like protein 1 (NELL1...
...option to license exclusive, worldwide rights to use NEL-like protein 1 (NELL1) to treat osteoporosis. Bone Biologics...
...bone regeneration in spinal fusion procedures, which is also under an exclusive license from UCLA. Bone Biologics...
BioCentury | Mar 7, 2016
Financial News

Bone Biologics completes private placement of convertible notes

...investor also received a five-year warrant to purchase up to 1.9 million shares at $2.05. Bone Biologics...
BioCentury | Mar 7, 2016
Financial News

Bone Biologics completes private placement

...million Price: $2.05 Shares after offering: 33.3 million Investors: Musculoskeletal Transplant Foundation; Orthofix Inc. Note: Bone Biologics...
BioCentury | May 11, 2015
Financial News

Bone Biologics completes venture financing

Bone Biologics Corp. , Edison, N.J. Business: Musculoskeletal Date completed: 2015-05-04 Type: Venture financing Raised: $2 million Investor: Hankey Capital Note: The convertible note matures on May 4, 2018, bears interest at the prime rate plus...
BioCentury | Nov 24, 2014
Company News

Bone Biologics management update

Bone Biologics Corp. , Edison, N.J. Business: Musculoskeletal Hired: Deina Walsh as CFO WIR Staff Musculoskeletal...
BioCentury | Mar 15, 2010
Financial News

Bone Biologics completes venture financing

Bone Biologics Inc. , Thousand Oaks, Calif. Business: Musculoskeletal Date completed: 3/10/10 Type: Venture financing Raised: Undisclosed Investor: Musculoskeletal Transplant Foundation Note: The investor also provided an undisclosed line of credit. WIR Staff Musculoskeletal Transplant...
BioCentury | Mar 15, 2010
Company News

Bone Biologics board of directors update

Bone Biologics Inc. , Thousand Oaks, Calif. Business: Musculoskeletal Appointed: Mark Spilker, VP of R&D at the Musculoskeletal Transplant Foundation WIR Staff...
BioCentury | Mar 2, 2009
Clinical News

Bone Biologics preclinical data

...Data from a primate model of spinal bone fusion surgery showed that Bone Biologics' UCB-1 combined with...
...matrix is from the Musculoskeletal Transplant Foundation, a non-profit consortium dedicated to providing allograft tissue. Bone Biologics...
Items per page:
1 - 10 of 18